DOvEEgene/WISE Genomics: Diagnosing Ovarian and Endometrial Cancer Early Using Genomics

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorMcGill University

About this trial

This study aims to develop and validate a test for detecting ovarian and endometrial cancers early. It relies on detecting somatic mutations that are associated with these cancers from a uterine pap test. A saliva sample is also collected that acts as an internal control and has the ability to detect deleterious germline mutations associated with common hereditary cancers (such as breast, ovarian, endometrial, colon, and pancreatic cancers). A machine learning classifier is then used to discriminate between cancer and benign disease.

Eligibility criteria

Qualifiers

Subjects should have suspected or confirmed cancer of the upper genital tract.

Participant will undergo surgery for tumour removal.

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

1,200 Participants
are grouped into 2 trial groups

Sponsors and collaborators

McGill University

Lead sponsor

McGill University Health Centre/Research Institute of the McGill University Health Centre

Collaborator